Viking Therapeutics

YTD

ALL

Trade Viking Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A.

CEO

Brian Lian

CEOBrian Lian

Employees

Employees36

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

2012

Founded2012

Employees

Employees36

VKTX Key Statistics

Market cap

4.18B

Market cap4.18B

Price-Earnings ratio

-16.25

Price-Earnings ratio-16.25

Dividend yield

—

Dividend yield—

Average volume

4.40M

Average volume4.40M

High today

$35.25

High today$35.25

Low today

$33.00

Low today$33.00

Open price

$34.96

Open price$34.96

Volume

4.39M

Volume4.39M

52 Week high

$81.73

52 Week high$81.73

52 Week low

$18.92

52 Week low$18.92

VKTX News

The Motley Fool 2d

Here's Why This Obesity Drug Company's Share Price Soared Today

The company had positive updates on its clinical trials. In common with many other small-cap biotech stocks, Viking Therapeutics' (VKTX +8.78%) share price ten...

Seeking Alpha 3d

Viking Therapeutics outlines completion of VANQUISH-1 enrollment by year-end while advancing novel VK2735 maintenance dosing study

Earnings Call Insights Viking Therapeutics outlines completion of VANQUISH-1 enrollment by year-end while advancing novel VK2735 maintenance dosing study Oct. 2...

TipRanks 3d

Viking Therapeutics reports Q3 EPS (81c), consensus (67c)

At September 30, Viking held cash, cash equivalents and short-term investments of $715M vs. $903M as of December 31, 2024. “During the first three quarters of 2...

Analyst ratings

94%

of 17 ratings

Buy

94.1%

Hold

5.9%

Sell

More VKTX News

Simply Wall St 4d

What Viking Therapeutics's New Maintenance Study for VK2735 Means for Shareholders

Viking Therapeutics recently announced the initiation of a Phase 1 exploratory maintenance dosing study for VK2735, its dual GLP-1/GIP agonist, to evaluate both...

People also own

Based on the portfolios of people who own VKTX. This list is generated using Robinhood data, and it’s not a recommendation.

Catalyst Pharmaceuticals

Novo Nordisk

Corbus Pharmaceuticals

Plug Power

Tilray Brands

Moderna